fda glp-1 compounding enforcement news New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA is moving to restrict

Incretin-based therapies: where will we be 50 years from now

At lower doses the risk may be smaller, but strength training and adequate protein intake are non-negotiable complements to treatment

Nascas animal studies suggest that acetyl-L-carnitine, a crucial mediator of fat metabolism and energy production throughout the body, plays a special role in the brain, where it works at least in part by preventing the excessive firing of excitatory nerve cells in brain regions called the hippocampus and frontal cortex

MIC injections MIC injections are lipotropic compounds designed to help the body burn fat more efficiently

Before receiving an IV treatment, it is essential to inform us of any food, medication, or drip ingredient allergies.